Nanotechnologies for Biological Applications

Day after day, our Customers & Partners are progressing to develop new therapies with Dendrigraft of L-Lysine from proof of concept at lab scale up to clinical trial in:

• Targeting Drug/Gene Delivery
• CNS Targeting
• MRI Contrast Agent for Medical Imaging
• Cell Culture
• In Vivo Antibody Production
• Growth Factors Controlled Release

More than 90 scientific publications about COLCOM's DGL are now available on our website.

Publication

Below, a recent publication about Gene Therapy for Myocardinal Infarction thanks to a double complexation made with DGL: a complexation with low molecular weight heparin to overcome the microvascular obstruction and another with miRNA to inhibit cardiomyocyte apoptosis.

Enjoy reading!

Gene Therapy

A Novel Anti-Coagulative Nanocomplex in Delivering miRNA-1 Inhibitor Against Microvascular Obstruction of Myocardial Infarction

2020, Hong et al.

Dendrigraft of L-Lysine

Over the years, COLCOM has developed its know-how to specifically customize DGL for health applications.

Customers & Partnerships